The United States Anti-Doping Agency (USADA) announced yesterday that Brazilian UFC middleweight Ricardo Abreu (5-1-0) was informed of a potential anti-doping infraction following an out-of-competition sample collected Dec. 21, 2016.
Abreu is already under a two-year suspension for anabolic steroid metabolites 19-norandrostrone (19-NA) and 19-noretiocholanolone were found in a June 3, 2016 sample. He is currently eligible to return July 1, 2018, but that could change with this new potential violation.
The UFC released the following statement on its website.
The UFC organization was formally notified today that the U.S. Anti-Doping Agency (USADA) has informed Ricardo Abreu of a potential Anti-Doping Policy violation stemming from an out-of-competition sample collection taken on December 21, 2016.
Abreu is currently serving a two-year suspension under the UFC Anti-Doping Program, after the anabolic steroid metabolites 19-norandrosterone (19-NA) and 19-noretiocholanolone were detected in a sample collected from Abreu on June 3, 2016. Under his current suspension, Abreu is not eligible to return to competition until July 1, 2018.
USADA, the independent administrator of the UFC Anti-Doping Policy, will handle the results management and appropriate adjudication of this case. It is important to note that, under the UFC Anti-Doping Policy, there is a full fair legal review process that is afforded to all athletes before any sanctions are imposed.
Consistent with all previous potential anti-doping violations, additional information or UFC statements will be provided at the appropriate time as the process moves forward.
Abreu’s last fight was a split-decision loss to Jake Collier at UFC Fight Night 68 in June 2015.
The process continues.